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Background: Arsenic trioxide (As2O3) is highly effective in treating acute promyelocytic leukemia (APL), but shows
more variable therapeutic efficacy for other types of hematological malignancies. Previously, we reported that As2O3
selectively eliminates pathogenic B220-expressing T cells in autoimmune MRL/lpr mice. We investigated herein the
relationship between As2O3 sensitivity of leukemic T-cell lines and the expression levels of the B220 isoform of
transmembrane tyrosine phosphatase CD45.
Methods: GSH content, O2− production, and B220, HSP70, Fas and FasL membrane expression was measured
by flow cytometry. Subcellular localization of B220 was determined by imaging flow cytometry. Cell death was
analyzed by morphological changes, annexin V and propidium iodide staining, and caspase 8 and 9 activation.
B220 mRNA expression was analyzed by RT-PCR. Activated NF-κB p50 was quantified by a DNA binding ELISA.
Results: We selected human (Jurkat, Jurkat variant J45.01, HPB-ALL) and mouse (EL-4, BW5147, L1210) T-cell lines
for their marked differences in As2O3 sensitivity over a large range of doses (1 to 20 μM). Differences in redox
status cannot explain the dramatic differences in As2O3 sensitivity observed among the T-cell lines. Unexpectedly,
we found that B220 is differentially induced on As2O3-treated T-cell lines. As2O3 treatment for 24 h induced low
(HPB-ALL), intermediate (Jurkat) and high (EL-4, BW5147) levels of B220 membrane expression, membrane-bound
HSP70 and cell death, but inhibited NF-κB p50 nuclear translocation. When high levels of B220 expression were
achieved with low doses of As2O3, the T-cell lines died by apoptosis only. When high doses of As2O3 were required to
induce B220 expression, leukemic T cells died by both apoptosis and necrosis.
Conclusions: Cellular redox status is not essential for As2O3 sensitivity of leukemic T cells, suggesting the existence of
additional factors determining their sensitivity to As2O3 cytotoxicity. Phosphatase B220 could be such a factor of
sensitivity. As2O3 treatment inhibits NF-κB p50 nuclear translocation, and induces B220 expression and cell death in a
dose and time dependent manner. The levels of B220 induction on leukemic T cells strictly correlate with both the
extent and form of cell death, B220 might therefore play a checkpoint role in death pathways.
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Arsenic trioxide (As2O3) shows impressive efficacy in the
treatment of patients with acute promyelocytic leukemia
(APL) [1-4]. As2O3 induces clinical remission in APL
patients by multiple mechanisms [5]. As2O3 promotes
cell differentiation at low concentrations [6,7], whereas
it induces apoptosis at higher concentrations [8]. The
high sensitivity of the APL cell line NB4 to As2O3-
induced cytotoxicity is associated to its low content of
reduced glutathione (GSH) and increased production
of reactive oxygen species (ROS) [9-11]. Although most
studies have been focused on the APL, As2O3 could be
beneficial against various hematopoietic malignancies and
solid tumors [12]. Moreover, we have shown that As2O3
also possesses immunomodulatory properties, and might
be a therapeutic agent for autoimmune diseases.
Indeed, As2O3 selectively eliminates the pathogenic B220-
expressing double negative (DN) CD4−CD8− T cells that
accumulate in autoimmune MRL/lpr mice due to the lpr
mutation of the death receptor Fas [13,14].
In normal murine and human T cells, CD4+ and CD8+
effector T cells massively induce the expression of trans-
membrane tyrosine phosphatase B220 before undergoing
apoptosis by the Fas/Fas ligand (FasL) pathway [15,16].
In Fas-deficient mice and patients, CD4+ and CD8+ ef-
fector T cells also express the B220 molecules at their
surface, but then they downregulate their CD4 or CD8
molecules while maintaining B220 plasma membrane
expression. B220 (or CD45RABC) is one of the five iso-
forms of the transmembrane tyrosine phosphatase CD45
found on lymphocytes. CD45 isoforms are generated by
cell-type and activation-state specific alternative splicing
of exons 4/A, 5/B, and 6/C encoding domains at the
NH2-terminus. Naive T cells express high molecular
weight CD45 isoforms (CD45RA or CD45RB) containing
the A domain in humans or the B domain in mice
whereas effector/memory T cells expressed the low mo-
lecular weight isoform CD45RO lacking extracellular do-
mains A, B and C. All CD45 isoforms share the same
intracellular region, which contains two phosphatase do-
mains. Although the function of each isoform remains
unknown, it is well established that CD45 phosphatase
activity is crucial for lymphocyte development, and anti-
gen and cytokine receptor signaling [17-19]. CD45 might
also regulate apoptosis of T and B lymphocytes [20-22].
In this study, we found that murine (EL-4, BW5147,
L1210) and human (Jurkat, CD45-deficient Jurkat vari-
ant, HPB-ALL) leukemic T-cell lines dramatically dif-
fered in their sensitivity to As2O3-induced cell death. In
contrast with previous findings in APL cell line NB4
[9,10], these differences in As2O3 sensitivity are inde-
pendent of intracellular GSH content and O2
− produc-
tion. Unexpectedly, we found that As2O3 differently
induced B220 cell surface expression in the leukemicT-cell lines in a dose- and time-dependent manner.
Moreover, the levels of B220 expression correlated with
the sensitivity of these T-cell lines to As2O3. Induction of
B220 membrane expression by As2O3 treatment is remin-
iscent of that observed on antigen-activated normal T-cell
blasts before undergoing apoptosis [15,16]. Therefore, the
leukemic T-cell lines were activated with calcium iono-
phore A23187, which triggers both cell activation and cell
death. Calcium ionophore A23187 also induced B220
expression and cell death, but with reverse efficiencies
in the leukemic T-cell lines compared to As2O3. In
addition, T-cell lines treated with A23187 most probably
died by an activation-induced cell death mechanism since
the T-cell activation marker CD69 is expressed before
B220 expression and cell death. In contrast, CD69 was not
detected on As2O3-treated cells, indicating that B220 ex-
pression occurs independently of leukemic T-cell acti-
vation. Surprisingly, we found that B220 is expressed
constitutively on L1210 T cells. L1210 cells were highly
sensitive to A23187 treatment whereas they were highly
resistant to As2O3 cytotoxicity, indicating that the consti-
tutive high-level expression of B220 did not favor cell
death triggered by As2O3. B220 induction on the T-cell
lines after treatment with As2O3 or calcium ionophore
A23187 strictly correlates with sensitivity to cell death,
emphasizing the role of B220 as a proapoptotic factor.
However, our data indicate that As2O3 and A23187 trigger
B220 induction and cell death through different upstream
signaling pathways. Different signaling pathways, such as
the c-Jun NH2-terminal kinase, have been implicated as
mediators of the cytotoxic effects of As2O3 in the APL
cell line NB4 [23]. Here, we show that high induction
of B220 expression on leukemic T cells is a determin-
ing factor leading to As2O3-triggered cell death. Thus
we hypothesize that B220 might play a checkpoint role
in death pathways.
Results
Human and mouse leukemic T-cell lines exhibit different
sensitivities to As2O3-induced growth inhibition and
cytotoxicity
In addition to APL-derived NB4 cells, As2O3 kills various
cancer cell types [12]. However, As2O3 sensitivity varies
considerably among tumor cell lines. In the present study,
we determined the sensitivity to As2O3-induced cytotox-
icity and growth inhibition of human (Jurkat and HPB-
ALL) and murine (EL-4, BW5147 and L1210) leukemic
T-cell lines. The five T-cell lines along with APL-derived
NB-4, known for its high sensitivity to As2O3 cytotoxicity,
were treated with As2O3 in doses ranging from 1 to
20 μM for 12, 24 and 48 h. Then, the percentage of living
cells was determined by Annexin V and propidium iodide
(PI) staining, and flow cytometry. We rapidly abandoned
treatments for 12 h and 48 h. Indeed, 100% EL-4 and
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low doses of As2O3, whereas HPB-ALL and L1210 cells
showed no sensitivity to As2O3 cytotoxicity before 24 h
of treatment, even with high doses (data not shown).
Because 24 h of treatment was the optimal time to ob-
serve significant differences in As2O3 cytotoxicity among
T-cell lines, this duration was used in subsequent experi-
ments. Sensitivity to As2O3 varied considerably among the
T-cell lines (Figure 1A). While around 3% NB4, 6% EL-4
and 13% BW5147 cells remained alive (Annexin V− and
PI−) at a concentration of 4 μM As2O3, remarkably, the
percentages of living cells were around 65% for Jurkat
cells, and between 80% and 90% for HPB-ALL and L1210
cells (Figure 1A). In addition, even at a dose of 20 μM,
20% L1210 and 40% HPB-ALL cells remained Annexin V−
and PI− (Figure 1A). The marked differences in As2O3
sensitivity among the T-cell lines can also be shown by
calculating the concentration of As2O3 that killed 50% of
the cells (IC50 value). The IC50 value of As2O3 was 1.5 μM
for EL-4, 2.5 μM for BW5147, 6 μM for Jurkat, 13 μM for
L1210 and 15 μM for HPB-ALL cells compared with
1.5 μM for the highly sensitive APL-derived NB4 cells
(Figure 1A). As2O3 cytotoxicity was also evaluated through
flow cytometric analysis of physical characteristics of
As2O3-treated T-cell lines using forward (FSC) and
side (SSC) scatters since dying or dead cells have lower
FSC and higher SSC than living cells. Depending upon
the dose of As2O3, two populations were observed on
the dot plots for FSC vs. SSC. The one containing large
cells (region R2) encompassed live cells, and the other
containing smaller cells (region R1) encompassed dying/
dead cells (Additional file 1: Figure S1A). We observed
that 50% of the cells of region R2 shifted to region R1
at 2.5 to 3 μM As2O3 for BW5147 and EL-4 cells,
6 μM for Jurkat cells, and 15 μM for L1210 and HPB-ALL
cells compared with 1.5 μM for the APL cell line NB4
(Figure 1B). In parallel, we determined As2O3-induced cell
growth inhibition by counting the total cell number in
each condition using flow cytometry. IC50 value for
growth inhibition was around 1 μM for NB4 and EL-4
cells, 3.5 μM for BW5147 cells, 8 μM for Jurkat, 15 μM
for L1210 and HPB-ALL cells. In summary, EL-4 and
BW5147 cells, and to a lesser extent Jurkat cells, are
among the most sensitive T-cell lines to As2O3-induced
cell growth inhibition and cytotoxicity, whereas L1210
and HPB-ALL cells are the most resistant.
Lack of evidence for the implication of GSH and O2
− in
As2O3-induced cytotoxicity in T-cell lines
As2O3 is able to impair the function of the mitochon-
drial respiratory chain, leading to increased O2
− produc-
tion [24]. O2
− is neutralized by intracellular GSH, which
is the major antioxidant produced by the cell. The de-
toxification function of intracellular GSH also includesthe cellular efflux of As2O3 [25]. Therefore, we per-
formed flow cytometry analysis of intracellular GSH
content and O2
− production in the T-cell lines before
and after treatment with As2O3 (Figure 2). APL-derived
NB4 cells were used as a reference because intracellular
redox status has been shown to be important in APL sen-
sitivity to As2O3 [9,10]. As observed in many cancer cells
[25], the untreated cell lines showed considerable hetero-
geneity in the intrinsic levels of O2
− production, with
untreated NB4 cells displaying the lower level of O2
−
(Figure 2A). In As2O3-treated APL-derived NB4 cells,
O2
− production increased with the dose of arsenic
(Figure 2B). In As2O3-sensitive EL-4 and BW5147 T-cell
lines, O2
− production was not increased by As2O3 treatment
even at the high dose of 15 μM (Figure 2B). In contrast,
in As2O3-resistant Jurkat and L1210 T-cell lines, O2
−
production was markedly increased (Figure 2B). There-
fore, these data indicate that the differences in As2O3
sensitivity between EL-4, BW5147, Jurkat and L1210
cells are not directly linked to increased production
of O2
−.
As expected, As2O3-sensitive APL-derived NB4 cells
displayed extremely low level of intrinsic GSH content
(Figure 2A). In contrast, the intrinsic GSH content in
untreated EL-4 and BW5147 T-cell lines were signifi-
cantly higher than in untreated HPB-ALL and L1210
T-cell lines (Figure 2A), although L1210 and HPB-ALL
cells were considerably more resistant to the cytotoxic
effect of As2O3 than EL-4 and BW5147 cells. At the
dose of 1 μM As2O3, levels of GSH were unaffected by
the treatment in the extremely sensitive NB4 cells, but
were markedly decreased in As2O3-sensitive BW5147
T cells and also, although to a lesser extent, in the
As2O3-resistant Jurkat cells (Figure 2B). Furthermore, in
the extremely resistant L1210 T cells, GSH production
was unchanged even at the high dose of 15 μM As2O3
(Figure 2B). Therefore, our data indicate that intracellular
GSH content alone cannot account for the differences in
As2O3 sensitivity observed among the five T-cell lines.
Induction of B220/CD45R expression on As2O3-treated
human and murine T-cell lines
Normal effector T cells undergoing apoptosis at the end
of an immune response express B220 on their cell surface.
These apoptotic B220+ T cells are solely found within the
FSCint/low SSChigh subset by flow cytometry analysis
[15,16]. Interestingly, we observed that As2O3 is also
able to induce cell-surface expression of B220 on EL-4,
BW5147, Jurkat and HPB-ALL T-cell lines in a dose-
dependent manner (Figure 3). However, B220 expression
levels differed significantly among these four T-cell lines.
Thus, a significantly higher percentage of EL-4 cells, and
to a lesser extent of BW5147 and Jurkat cells, expressed
B220 compared to HPB-ALL cells (for instance, see 2 μM
Figure 1 Viability and cell morphology of various T-cell lines cells upon As2O3-treatment. (A) APL-derived NB4 cells as well EL-4, BW5147,
L1210, Jurkat (clone E6-1), CD45-deficient Jurkat variant (J45.01) and HPB-ALL T-cell lines were treated with As2O3 for 24 h with doses ranging
from 1 to 20 μM. T-cell lines were then stained with Annexin V and PI, and the percentages of living cells (Ann V− PI−) determined by flow cytometry.
At least 20,000 events were analyzed for each sample. Graphs show mean percentages ± SE of Ann V− PI− cells from more than 4 independent
experiments. IC50 in the graphs indicates the concentration of As2O3 that kills 50% of the cells. (B) Cells were analyzed by flow cytometry
with respect to size (FSC) and granulosity (SSC). Regions R1 and R2 identified on a FSC vs. SSC dot plot encompassed cells with FSCintermediate(int)/lowSSChigh
and FSChighSSClow, respectively. At least 20,000 events were analyzed for each sample. Graphs show mean percentages ± SE of cells located in region R1
(◊) and R2 (■) at the indicated concentration of As2O3. Numbers in the graphs indicate the concentration of As2O3 at which 50% of the cells shifted from
region R2 to region R1. Four independent experiments were performed for NB4 and J45.01 cells, and more than 10 for EL-4, BW5147, L1210, Jurkat and
HPB-ALL cells.
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Figure 2 Intracellular levels of O2
− and GSH in cell lines before and after As2O3 treatment. Intracellular levels of O2
− and GSH were
measured using CMFDA or DHE fluorescent probes and flow cytometry. (A) Untreated APL-derived NB4 cells and T-cell lines were examined for
intrinsic levels of O2
− production and GSH content. Histograms obtained with specific fluorescent probes (colored histograms) are overlaid on
fluorescence histograms of unstained cells (black dotted histogram). A total of 20,000 events were analyzed for each histogram. Graphs report
mean ± SE (n = 3 independent experiments) of integrated MFI values for O2
− production and GSH content. The integrated MFI is calculated by
multiplying the frequency of positive cells by the MFI of O2
− and GSH. Asterisks denote statistically significant differences for levels of GSH or O2
−
between leukemic T-cell lines and APL-derived NB4 cells: *p ≤0.05; ***p ≤0.001. (B) O2
− production and GSH content were examined in APL-derived
NB4 cells and T-cell lines treated with 1 μM to 15 μM As2O3 for 24 h. Graphs report mean ± SE (n = 3 independent experiments) of integrated MFI values
for O2
− production and GSH content.
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T cells were found in both gate R1 and R2 that contained
FSCint/low SSChigh dying cells (Figure 3) and FSChigh SSClow
living cells (data not shown), respectively, although the
numbers were significantly higher in gate R1. As2O3 also
induces B220 expression at the mRNA level in a dose- and
time-dependent manner. High levels of B220 mRNA were
found in EL-4 and BW5147 within 3 h of treatment with
1 μM As2O3. Higher doses of As2O3 (e.g., 4 μM for 3 h) or
longer treatment (e.g., 1 μM for 9 h) resulted in increased
levels of B220 mRNA (Additional file 1: Figure S1C). In
contrast, As2O3 did not induce B220 expression on APL-
derived NB4 cells (data not shown). To confirm that
A2O3-induced cytotoxicity in leukemic T cells and B220
expression are mechanistically related, we analyzed CD45-
deficient Jurkat cells (clone J45.01) for their As2O3 sensitiv-
ity over a large range of doses (1 to 20 μM). As shown in
Additional file 1: Figure S1B, J45.01 T-cell line displays a
strong reduction in the expression level of CD45 per cell
(MFI) compared to wild-type Jurkat cells (MFI J45.01: 40;MFI Jurkat: 1528; MFI isotype control: 5). The IC50 value
for cytotoxicity was around 12 μM for J45.01 compared to
6 μM for wild-type Jurkat cells, corroborating the critical
role of the B220 isoform of CD45 in the resistance/sensitiv-
ity of leukemic T cells to As2O3.
Unexpectedly, we also found that L1210 T cells consti-
tutively express B220 at the plasma membrane. L1210
cells undoubtedly belong to the T-cell lineage because they
coexpress the mouse pan T-cell marker CD90 (Additional
file 2: Figure S2A). To the best of our knowledge, we have
shown for the first time that B220 can be constitutively
expressed at high levels on T cells, in the absence of exter-
nal stimulation. As2O3 treatment did not change either
the percentages of B220+ L1210 cells, or the expression
level of B220 per cell (MFI) (Additional file 2: Figure S2B).
Furthermore, we have compared the subcellular
localization and distribution of B220 molecules that
were either constitutively expressed on L1210 cells or
As2O3-induced on EL-4 cells, using ImageStream de-
vice, which allows simultaneous flow cytometry and
Figure 3 Induction of phosphatase B220/CD45R and HSP70 on As2O3-treated T-cell lines. EL-4, BW5147, Jurkat, CD45-deficient Jurkat variant
(J45.01) and HPB-ALL T-cell lines were treated with As2O3 for 24 h in doses ranging from 1 to 20 μM. (A) T-cell lines were then stained with PE-conjugated
anti-B220/CD45R mAb or PE-conjugated rat IgG2a isotype control, and then analyzed by flow cytometry with respect to size (FSC) and B220 expression.
FSC vs. B220 contour plots were used to determine the percentage of B220+ cells in region R1 (FSCint/lowSSChigh). At least 20,000 events were analyzed per
sample. Squares in contour dots contain B220+ cells, and are drawn relative to the location of the cells in FSC vs. IgG2a isotype control contour
plots. Numbers in the squares indicate the percentages of B220+ cells. Graphs report mean percentages ± SE (n =10 independent experiments)
of B220+ cells versus the dose of As2O3. (B) T-cell lines were stained with APC-conjugated anti-B220 and FITC-conjugated anti-HSP70 antibodies or
FITC-conjugated IgG and APC-conjugated IgG2a isotype control. FSC vs. SSC dot plots were used to define gates R1 and R2 with FSCint/lowSSChigh and
FSChighSSClow, respectively. HSP70 vs. B220 dot plots were then gated in R1 and R2 to determine the percentages of cells expressing HSP70, B220 or
both. At least 20,000 events were analyzed for each sample. Graphs report the percentages of cells co-expressing B220 and HSP70 in gates R1 (◊) or R2
(■) versus the dose of As2O3.
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cells. Whole cell and nuclear boundaries were identified
using brightfield image and DAPI staining, respectively. In
the absence of As2O3 treatment, no labeling with anti-
B220/CD45R mAb was observed in EL-4 cells (Figure 4A).
In contrast, in untreated L1210 cells and 2 μM As2O3-
treated EL-4 cells, B220 molecules were expressed at high
levels with a restricted localization to the cell surface
(Figure 4A and B), confirming the results obtained by
flow cytometry. However, B220 molecules appeared
less uniformly distributed over the plasma membrane
of EL-4 cells (Figure 4A) than L1210 cells (Figure 4B).
Thus, L1210 cells showed a uniform fluorescence atthe periphery of the cell, whereas a variable number of
bright spots of fluorescence were distributed at the
periphery of EL-4 cells.
Duration of B220/CD45R membrane expression after
As2O3 treatment
To determine the duration of B220 expression following
As2O3 treatment, EL-4 and Jurkat cells were cultured in
the presence of 1 to 8 μM As2O3 for 24 h. Cells were
then extensively washed to eliminate As2O3, and cul-
tured in complete medium for 9 additional days. As2O3
treatment for 24 h induced B220 expression in a dose-
dependent manner (Additional file 3: Figure S3, graphs),
Table 1 Opposite effects of As2O3 or Calcium ionophore A23187 on a panel of leukemic T-cell lines

















EL-4 63 No 35 70 7 Yes no 1
BW5147 30 No 20 39 19 Yes no 25
Jurkat clone
E6-1
22 No 10 12 30 Yes no 28
HPB-ALL 10 No 3 5 80 Yes no 75
L1210 Constitutive
expression
No 5 10 Constitutive
expression
Yes no 55
*a clinically relevant concentration of As2O3.
**percentage of positive cells determined by flow cytometry.
***percentage of PI+ cells (either Annexin V− or Annexin V+) determined by flow cytometry.
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ported in Figure 3. On day 1 post-treatment, and at con-
centrations of 1 μM and 8 μM As2O3, the percentages of
B220+ EL-4 cells were around 50% and 95%, respectively.
One week later, the percentage of B220+ EL-4 cells fell
below 15% at 1 μM As2O3, whereas it remained at 90% at
the concentration of 8 μM (Additional file 3: Figure S3,
graphs). Likewise in Jurkat cells, on day 7 post-treatment,
around 50% of cells treated with 8 μM As2O3 expressed
B220 (Additional file 3: Figure S3, dot plots and graph),
while B220 could no longer be detected on Jurkat cellsFigure 4 Subcellular localization of constitutively expressed and As2O
(2 μM for 24 h) EL-4 cells (panel A), and untreated L1210 cells (panel B) w
dye. Samples were then analyzed on the ImageStream system. At least 10,000
B220-PE positive cells were gated (gate R2) according to the principle fo
determined using PE-conjugated rat IgG2a isotype control. Representati
(blue) fluorescence and composite images of B220/DAPI are shown on ptreated with 1 to 4 μM As2O3 (Additional file 3: Figure S3,
graph). The loss of B220 expression on EL-4 and Jurkat
cells was accompanied by a decreased cell number in gate
R1 (FSCint/low SSChigh) and an expansion of viable cells in
gate R2 (Additional file 3: Figure S3, dot plots, see days 7
and 9). The duration of B220 expression in gate R1 was
dependent on the dose of As2O3 treatment. Thus, a longer
duration of B220 expression was associated with a higher
concentration of As2O3, and a higher number of B220
+
cells at the time of As2O3 removal. The decrease in the
percentages of B220+ cell population could be due to the3-induced B220/CD45R molecules. Untreated and As2O3-treated
ere stained with PE-conjugated anti-B220/CD45R mAb and DAPI nuclear
images were collected per sample at 40× and 60× magnification.
r flow cytometry as shown on histogram. Background staining was
ve cell images of brightfield illumination, B220-PE (red) and DAPI
anel A and B.
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remaining B220− cells. However, even on day 9 post-
treatment, EL-4 and Jurkat cells had not fully recovered
their initial proliferative capacity (data not shown). Our
data suggest that dead B220+ T cells release their As2O3
content into the medium, which is subsequently recap-
tured by living B220-negative T cells. The amount of re-
leased As2O3 is dependent on the dose used at the time of
treatment.
Expression of membrane-bound HSP70 on As2O3-treated
T-cell lines parallels the induction of B220/CD45R
Heat shock protein 70 (HSP70) is upregulated intracellu-
larly in respond to a variety of stresses including chem-
ical or chemotherapeutic agents. HSP70 proteins can
also be found at the cell surface of some tumor cells.
Notably, membrane-bound HSP70 has been shown to
elicit antitumor immunity [26,27]. Therefore, HSP70 and
B220 expression was determined by flow cytometry on
the plasma membrane of the T-cell lines treated with
As2O3 for 24 h in doses ranging from 1 to 20 μM.
HSP70 was not detected on untreated T-cell lines
(Figure 3B). As2O3 treatment upregulated membrane-
bound HSP70 in EL-4, BW5147, Jurkat and HPB-ALL
cells in a dose-dependent manner. The expression pattern
of HSP70 was parallel to that of B220, and HSP70 was
expressed in B220+ cells only (Figure 3B). As observed for
B220 expression, a significantly higher percentage of EL-4
cells, and to a lesser extent of Jurkat cells, than HPB-ALL
cells expressed HSP70 (Figure 3B) (Table 1). L1210
cells, constitutively expressing B220, had a low level
of expression of membrane-bound HSP70 (Additional
file 2: Figure S2C) similar to HSP70 levels observed in
HPB-ALL cells. Therefore, As2O3 treatment induced
both HSP70 and B220 membrane expression and the
levels of expression correlated with leukemic T-cell
lines sensitivity to As2O3.
B220/CD45R expression on As2O3-treated leukemic T cells
is not a direct consequence of T-cell activation unlike the
expression induced by the calcium ionophore A23187
The induction of B220 on EL-4, BW5147, Jurkat and
HPB-ALL leukemic T cells treated with As2O3 is suggest-
ive of the induction observed on normal T cells entering
apoptosis after repeated activation by their antigen. T-cell
activation can be evidenced by measuring the expression
of surface marker CD69 [28]. Therefore, we have analyzed
the induction of CD69 on the T-cell lines treated with
As2O3 as well as with PMA and calcium ionophore
A23187 as positive controls. As expected, the activation of
leukemic T cells with 10 ng/ml of PMA for 5 h induced a
strong expression of the activation marker CD69 in cells
within region R2 only, which encompasses living cells. In
contrast, we did not detect the expression of CD69 byflow cytometry on the cell surface of As2O3-treated
leukemic T cells, whatever the doses tested (1 to 20 μM,
data not shown), suggesting that the induction of B220 ex-
pression by As2O3 is not a direct consequence of T-cell
activation.
As observed with PMA, activation of the leukemic
T-cell lines with 100 nM to 800 nM of the calcium
ionophore A23187 for 24 h induced the expression of
CD69 on EL-4, BW5147, L1210, and Jurkat cells and
also, to a lesser extent, on HPB-ALL cells (Table 1).
However, the number of CD69+ cells decreased with
the dose of A23187, and hardly any CD69+ cells were
detected at the higher dose of A23187 (data not shown).
In contrast, a dose-dependent expression of B220 was
detected on EL-4, BW5147, Jurkat and HPB-ALL cells,
although significant differences were observed in the
percentages of B220+ cells among T-cell lines (Figure 5).
Thus, 50% of B220+ cells were detected at a dose of
A23187 around 50 nM for HPB-ALL cells, 100–130 nM
for Jurkat cells, 275 nM for BW5147 and 600 nM for EL-4
cells (Figure 5, see B220 induction). Interestingly, at
around the same dose of A23187 that induced B220
expression, 50% of HPB-ALL, Jurkat, BW5147 and EL-4
cells died (Annexin V and PI staining, Figure 5, see Cell
viability) or shifted from region R2 to R1 on the FSC vs.
SSC dot plots (Figure 5, see Cell morphology). In contrast
to As2O3, the constitutive expression of B220 on L1210 T
cells renders these cells remarkably sensitive to A23187
(Figure 5, see Cell viability and Cell morphology). There-
fore, B220 expression level strictly correlates with the sus-
ceptibility of T cells to die following A23187 activation,
suggesting an interesting link between transmembrane
phosphatase B220 expression and cell death. Moreover, in
contrast with As2O3 treatment, membrane-bound HSP70
was not upregulated following treatment with calcium
ionophore A23187, even on the B220+ T-cell subpopula-
tions (data not shown).
Relative contributions of apoptosis and necrosis in T
leukemia cell death induction by As2O3 or calcium
ionophore A23187
It is widely considered that As2O3 exerts its cytotoxic ac-
tivity by triggering cell apoptosis [12]. However, it has
been reported that As2O3 can induce cell death inde-
pendently of caspase activity [29,30]. We have deter-
mined whether the apoptotic and/or necrotic pathways
were activated upon As2O3 or calcium ionophore A23187
treatment in EL-4, Jurkat, HPB-ALL and L1210 cells.
Because BW5147 cells displayed similar sensitivity to
As2O3 and A23187 as EL-4 and Jurkat cells, respect-
ively, the latter two T-cell lines were preferentially
chosen for subsequent experiments. In the presence of
As2O3 or A23187, no PI
+ cells (either Annexin V− or
Annexin V+) were detected in the B220-negative cell
Figure 5 Cell viability, cell morphology and B220/CD45R induction in T-cell lines stimulated with calcium ionophore A23187.
Jurkat, HPB-ALL, L1210, EL-4 and BW5147 cells were treated with Calcium ionophore A23187 for 48 h in doses ranging from 100 to 800 nM.
Cell viability measurement. Untreated and A23187-treated cells were stained with Annexin V and PI, and the percentages of living cells (Ann V− PI−)
determined by flow cytometry. Graphs show mean percentages ± SE of Ann V− PI− from 4 independent experiments. Cell morphology analysis. Untreated and
A23187-treated cells were analyzed by flow cytometry with respect to size (FSC) and granulosity (SSC). Regions R1 (◊) and R2 (■) identified on
FSC vs. SSC dot plots encompassed cells with FSCint/lowSSChigh and FSChighSSClow, respectively. B220 induction. Untreated and A23187-treated
T-cell lines were stained with anti-B220/CD45R mAb and analyzed by flow cytometry. Graphs report mean percentages ± SE (n = 4 independent
experiments) of B220+ EL-4, BW5147, Jurkat and HPB-ALL cells at the indicated concentration of A23187. At least 20,000 events were analyzed
per sample in all experiments reported in the graphs.
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B220+ cell subpopulation, the IC50 value of As2O3 that
causes either apoptotic or necrotic cell death was 1.5 μM
for EL-4 cells, 8 μM for Jurkat cells and 9 μM for L1210
cells. For B220+ HPB-ALL cells, even at the higher dose of
20 μM As2O3, only 39 ± 2.5% of the cells were killed
(Figure 6A). Furthermore, to discriminate between late
apoptosis (PI+/Annexin V+) and necrosis (PI+/Annexin
V−), we analyzed the levels of active initiator caspases
8 and 9 in the B220+ PI+-cell subpopulation. Significa-
tive differences were observed between the T-cell lines, even
though the levels of active caspase 8 and/or 9 increased with
the dose of As2O3 (Figure 6B and C). Thus, EC50 for caspase
8 activation was 2 μM for EL-4 cells and 6.5 μM for Jurkat
cells (Figure 6B). To activate caspase 9 in these T-cell lines,
almost twice as much As2O3 was required compared with
caspase 8 (Figure 6C). Even at the higher dose of 20 μM
As2O3, only 16 to 19% of HPB-ALL cells and ~40% of
L1210 cells contained active caspase 8 or caspase 9
(Figure 6B and C). Since As2O3 can also induce celldeath independently of caspase activity [30], we have deter-
mined the percentages of necrotic cells (PI+/Annexin V− or
PI+/active Caspase−). No necrotic cells were detected in
As2O3-treated EL-4 cells. In contrast, 4 to 29% necrotic
cells were detected in As2O3-treated Jurkat, HPB-ALL and
L1210 cells (Figure 6D). In agreement with Figure 4, the
IC50 value of calcium ionophore A237187 that cause either
apoptotic or necrotic cell death was between 80 nM and
150 nM for L1210, HPB-ALL and Jurkat cells compared
with around 600 nM for EL-4 cells (Figure 6A). The relative
contributions of apoptotic and necrotic cell death in cal-
cium ionophore A23187 cytotoxicity showed an opposite
pattern compared with As2O3 cytotoxicity. In the presence
of calcium ionophore A23187, up to 32% necrotic cells
were detected in EL-4 cells, whereas no necrotic cells were
detected in HPB-ALL cells and less than 8% were detected
in L1210 and Jurkat cell lines (Figure 6D). Moreover, EL-4
cells did not contain active caspase 8 and 9, whereas high
levels of active caspase 8 and 9 were detected in L1210,
HPB-ALL, and Jurkat T-cell lines (Figure 6B and C).
Figure 6 Contribution of apoptosis, necrosis and NF-κB p50 pathways in the cytotoxicity of As2O3 or calcium ionophore A23187. (A to
E) EL-4 (♦), L1210 (◊), Jurkat (■) and HPB-ALL (□) T-cell lines were treated with 1 to 20 μM As2O3 for 24 h or 100 to 800 nM A23187 for 48 h. Cells
treated with As2O3 or A23187, or left untreated, were subsequently stained with PI and CaspaTag Caspase 8 or Caspase 9 fluorescein in situ
fluorescence assay kit. The stained cells were analyzed by flow cytometry in order to determine the percentages of dead cells (either apoptotic or
necrotic cells, graphs A) (n = 5 independent experiments), the percentages of PI+ apoptotic cells containing active caspase 8 (graphs B) or active
caspase 9 (graphs C), the percentage of necrotic cells (graphs D). Human or murine FasL expression was detected using anti-FasL mAb and
flow cytometry (histograms E). Histograms obtained with PE-conjugated Armenian hamster (clone MFL3) or mouse (clone NOK-1) anti-FasL
mAb (open histogram) are overlaid on histograms obtained with PE-conjugated Armenian hamster or mouse IgG1 isotype control (shaded
histogram) (n = 3 independent experiments). At least 20,000 events were analyzed for each sample. (F). Nuclear extracts were prepared from
NB4, EL-4, BW5147, Jurkat and J45.01 cells treated with 1 to 12 μM As2O3 for 24 h. Levels of NF-κB p50 in 5 μg of nuclear extracts were
quantified by a DNA binding ELISA assay. Results are representative of two other experiments.
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expression were achieved with low doses of As2O3 or
calcium ionophore A23187, the leukemic T-cell lines
died by apoptosis only. When high doses of As2O3 or
calcium ionophore A23187 were required to induce B220
expression, the T-cell lines died by both apoptosis and ne-
crosis. The constitutive expression of B220 on L1210 cells
did not favor apoptosis or necrosis, and cells died by a
combination of the two. Taken together, our data suggest
that transmembrane tyrosine phosphatase B220 plays a
checkpoint role in apoptotic pathways since its expression
is markedly and rapidly induced on the surface of T cells
undergoing apoptosis.Expression of Fas and Fas ligand upon treatment with
As2O3 or A23187
The presence of active initiator caspase 8 in the T-cell
lines treated with A23187 or As2O3 suggested that cells
entered apoptosis upon engagement of death receptors
such as Fas. In normal T cells, Fas receptor is constitu-
tively expressed whereas its ligand, FasL, is expressed
after T cell activation. The five T-cell lines were treated
or not with As2O3 or calcium ionophore A23187 for
24 h and 48 h, and the levels of Fas and FasL expression
were determined by flow cytometry. Fas receptor is
strongly expressed on untreated Jurkat cells, weakly
expressed on untreated HPB-ALL cells, and not detected
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cant modulation in Fas receptor expression was ob-
served after treatment with As2O3 or A23187 (data not
shown). Its ligand, FasL, is not expressed on untreated
T-cell lines. Upon treatment with 2 μM As2O3 for 24 h,
only the highly As2O3-sensitive EL-4 T-cell line expressed
FasL, with 100% of EL-4 cells being FasL positive although
weakly (Figure 6E). FasL+ EL-4 cells were equally detected
in regions R1 and R2 (data not shown), suggesting that
FasL is expressed before apoptosis. FasL-expressing
BW5147, L1210, Jurkat and HPB-ALL cells were not
detected even after 48 h of treatment with As2O3 (data
not shown).
Treatment with the calcium ionophore A23187 upreg-
ulated FasL expression on EL-4, BW5147 and L1210
cells (Figure 6E and Additional file 2: Figure S2D), but
not on Jurkat and HPB-ALL cells (data not shown).
While 24 h of treatment were sufficient to induce FasL
expression on BW5147 and EL-4 cells, 48 h were required
to induce such expression on L1210 cells (Additional
file 2: Figure S2D). However, the expression levels of
FasL were significantly higher on BW5147 cells than
on EL-4 and L1210 cells. In addition, FasL upregula-
tion was achieved using a concentration of calcium
ionophore A23187 around 4 and 8 times higher in EL-4
cells and L1210 cells, respectively, than in BW5147 cells.
FasL-expressing EL-4, BW5147 and L1210 cells were
equally detected in regions R1 and R2 (data not shown).
The expression of FasL on EL-4 cells treated with As2O3
or A23187, and on BW5147 and L1210 cells only when
treated with A23187, strongly suggest that As2O3 and
A23187 trigger FasL expression through different signal-
ing pathways. Furthermore, the absence of either Fas or
FasL, or both, on A2O3- or A23187-treated cells indicates
that their activation of caspase 8 is independent of the
Fas/FasL pathway and must depend on other death
pathway.
As2O3 treatment represses nuclear translocation of
NF-κB p50
NF-κB activity regulates the apoptosis of various cancer
cell lines. Activation of NF-κB can promote or prevent
apoptosis, depending on the stimuli utilized and the cell
type [31]. Conflicting results have been published on the
activation status of NF-κB in As2O3-treated leukemia T
cells. One report has shown that As2O3 treatment mark-
edly decreases constitutive NF-κB activation [32]. In an-
other study, the authors could not detect any decrease
in the translocation of the p65 subunit of NF-κB [33].
This discrepancy may be due to differences in the doses
of As2O3 used to treat leukemic T cells. Therefore, we
have quantified NF-κB p50 in nuclear extracts from
NB4, EL-4, BW5147, Jurkat (clone E6-1) and CD45-
deficient variant (clone J45.01) treated with a large rangeof doses (i.e. 1 μM to 12 μM). We found that As2O3
treatment represses nuclear translocation of NF-κB p50
in As2O3-treated T cells in a dose-dependent manner
(Figure 6F). Importantly, nuclear translocation of NF-κB
p50 was strongly increased in the CD45-deficient Jurkat
T-cell line (clone J45.01) treated with As2O3 compared
to wild-type Jurkat cells (Figure 6F). Thus, after a treat-
ment with 6 μM As2O3 (IC50 value for the cytotoxic ef-
fect of As2O3 on Jurkat cells) J45.01 cells contained
markedly more nuclear NF-κB p50 (about 3 times more)
than wild-type Jurkat cells, suggesting a link between
B220 and NF-κB signaling pathways.
Discussion
In APL-derived NB4 cells, As2O3 triggers apoptosis at
concentrations of 0.5 to 2 μM [8]. The cytotoxic proper-
ties of As2O3 are not restricted to APL, and As2O3 in-
duces apoptosis in various types of hematopoietic and
solid tumors [12]. However, hematologic tumor cells
vary considerably in their sensitivity to As2O3. To gain
insight into the mechanisms underlying the As2O3 sensi-
tivity of malignant T cells, we firstly selected two human
(Jurkat and HPB-ALL) and three murine (EL-4, BW5147
and L1210) T-cell lines for their marked differences in
sensitivity to As2O3 cytotoxicity over a large range of
doses (i.e. 1 μM to 20 μM). Thus, 50% of EL-4 cells are
killed at a clinically relevant concentration of about
1–2 μM As2O3, whereas concentrations of ~2.5 μM
As2O3 for BW5147, ~6 μM As2O3 for Jurkat and ~12–
15 μM As2O3 for L1210 and HPB-ALL T-cell lines are re-
quired to kill approximately 50% of the cells. Using this
tumor panel, we have shown that: 1) differences in the
intracellular levels of GSH and O2
− are not sufficient to
account for their differences in As2O3 sensitivity; 2) trans-
membrane tyrosine phosphatase B220 is induced on EL-4,
BW5147, Jurkat and HPB-ALL T-cell lines, but not APL-
derived NB4 cells, upon treatment with As2O3 in a dose
and time dependent manner; 3) the degree of B220 induc-
tion on the T-cell lines is strongly correlated with the
sensitivity to As2O3 cytotoxicity; 4) surprisingly, B220
is constitutively expressed on the L1210 T-cell line; 5)
membrane-bound HSP70, known to induce antitumor
immunity, is upregulated by As2O3 in parallel with
B220 induction; 6) initiator caspases 8 and 9 are acti-
vated by As2O3 in the T-cell lines where this activation
parallels B220 induction, but not in L1210 cells; 7)
As2O3 represses nuclear translocation of NF-κB p50 in
a dose dependent manner; 8) FasL upregulation by
As2O3 is found on Fas-negative EL-4 cells only, indi-
cating that caspase 8 activation is most probably inde-
pendent of the Fas/FasL pathway [34]. However, the
absence of FasL on some T-cell lines (either human or
murine) might be due to the rapid shedding of FasL by
protease activities induced by As2O3 or calcium ionophore
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treatment with Ionomycin or ATP [35].
Contradictory data have been published on the efficacy
of As2O3 treatment against tumors belonging to the
lymphoid lineages. Evidence for a pro-apoptotic effect of
As2O3 against human malignant T- and B-cell lines [36],
cutaneous T-cell lymphoma [37] or HTLV-I-associated
adult T-cell leukemia [38] was provided by in vitro stud-
ies. However, it has been shown, in a multi-institution
phase II study, that As2O3 exhibits limited efficacy
against lymphoid malignancies, even though the patients
received ascorbic acid in addition to As2O3 [39]. The au-
thors of this clinical study expected that agents such as
ascorbic acid, which depletes intracellular GSH, could
potentiate arsenic-induced apoptosis, since it has been
described previously [10] that the sensitivity of cells to
As2O3 are inversely correlated with their intracellular
GSH content. As2O3 interacts with sulfhydryl (SH) groups
of biologically active molecules. The binding of As2O3 to
the SH group of GSH could cause a drastic decrease in
the capacity to scavenge ROS in cells with a low basal
GSH content, resulting in overproduction of intracellular
ROS that could trigger cell apoptosis. However, our
present study shows that EL-4 and BW5147 T-cell lines,
which were the most sensitive to As2O3-induced cytotox-
icity among the cells lines studied (IC50 of approximately
1 to 2.5 μM) had the highest baseline GSH content
(Figure 2). Likewise, L1210 and HPB-ALL T cells that
were significantly more resistant to As2O3 cytotoxicity
(IC50 of approximately 12 to 15 μM) had significantly
lower baseline GSH content than EL-4 and BW5147
cells (Figure 2). In the presence of As2O3, intracellular
GSH content was differently modulated in the T-cell
lines, but without any correlation with their As2O3
sensitivity. Thus, GSH level in the highly sensitive NB4
cell line was unaffected by the dose of 1 μM As2O3,
whereas it was markedly decreased in the BW5147 T-cell
line and also, although to a lesser extent, in the resistant
Jurkat cells (Figure 2). Because intracellular GSH content
did not appear to be a key factor in determining As2O3
sensitivity of these five leukemia T-cell lines, we further
explored the evolution of O2
− production upon treatment
with As2O3. The five T-cell lines showed a great hetero-
geneity in levels of intrinsic O2
− production (Figure 2),
which, interestingly, were 2 to 8 times higher than in
APL-derived NB4 cells. As expected, the levels of O2
− were
significantly increased in APL-derived NB4 cells in the
presence of As2O3. In T-cell lines, the situation was more
complex. While the levels of O2
− increased significantly, in
Jurkat, L1210, and to a lesser extent HPB-ALL T cells
treated with As2O3, they remained unchanged in EL-4
and BW5147 T cells. Therefore, the changes of O2
− pro-
duction upon treatment with As2O3 are not correlated
with the differences in As2O3 sensitivity that we observedamong the five T-cell lines. In contrast to other tumor
cells [5], neither the intracellular GSH content nor the
production of O2
− had any decisive effect on As2O3-
induced apoptosis of the five T-cell lines studied.
Therefore, our findings suggest that the depletion of
leukemic T cells in their intracellular GSH content by
ascorbic or butyric acid are not necessarily relevant to
potentiate the cytotoxic effect of As2O3. Furthermore,
it has been reported that the expression level of aqua-
glyceroporin (AQP)9, a transmembrane protein that
controls arsenic transport, correlated positively with
As2O3-induced cytotoxicity in myeloid and lymphoid
leukemia cell lines [40]. In contrast, the overexpres-
sion of AQP9 in melanoma cells significantly increased
the resistance to arsenite-induced apoptosis [41]. These
reports prompted us to determine the levels of AQP9
mRNA by semi-quantitative RT-PCR in EL-4, BW5147,
L1210, Jurkat and HPB-ALL T-cell lines, and in APL-
derived NB4 cells. However, we did not find any correl-
ation between the expression levels of AQP9 mRNA and
the As2O3 sensitivity in the T-cell lines (unpublished data).
Therefore, our data strongly suggest the existence of add-
itional factors determining the sensitivity of T cells to
As2O3 cytotoxicity. Herein, we have hypothesized that
phosphatase B220 could be such a factor, since we have
shown previously that treatment with As2O3 of auto-
immune MRL/lpr mice selectively eliminates pathogenic
B220-expressing T cells in vivo [13,14].
Normal effector T cells entering apoptosis after re-
peated activation by their antigen express the tyrosine
phosphatase B220 on their surface [15,16,42], suggesting
a role for B220 induction in the transition from activa-
tion to apoptosis. On the other hand, B220 is the iso-
form of CD45 predominantly expressed on pathogenic
DN T cells from patients and mice with a deficiency in
the death receptor Fas, or its ligand FasL. FasL-deficient
mice (gld mutation) with only one functional CD45
allele (gld/gld, CD45+/−) display a strong reduction
in the pathogenic DN T-cell population [43], suggest-
ing that CD45 is an important regulator of T-cell
apoptosis or a survival factor for T cells. Whether and
how B220 expression on T cells regulates signaling for
death or survival remains unknown. The induction of
B220 and FasL (in EL-4 cells) as well as the activation of
initiator caspase-8 in As2O3-treated leukemic T-cell lines
were reminiscent of apoptosis in normal effector T cells
triggered by repeated antigenic stimulation. Therefore,
leukemic T-cell lines were activated with calcium iono-
phore A23187, a well-known trigger for T-cell activation
and death. Importantly, we found that As2O3 and calcium
ionophore A23187 have opposite efficiencies on the T-cell
lines, evidenced by the induction of B220, activation
marker CD69 and membrane-bound HSP70 expression,
and cell death (data summarized in Table 1). While both
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EL-4 cells after treatment with As2O3, they were only
slightly induced after treatment with calcium ionophore
A23187. The complete reverse situation was observed in
HPB-ALL cells, indicating that A23187 and As2O3 had
opposite effects on B220 expression and cell death on the
same leukemic T-cell panel. Moreover, treatment with
A23187, but not As2O3, induced the activation marker
CD69 on T-cell lines before B220 expression and cell
death, indicating that A23187, but not As2O3, kills the
T-cell lines by an activation-induced cell death mechanism.
HSP70 is overexpressed in various cancer cells [44].
HSP70 inhibits apoptosis by modulating multiple events
within apoptotic pathways, which might promote cancer
development [45,46]. However, a tumor-specific plasma
membrane form of HSP70 has been described [44,47],
which facilitates tumor rejection by the immune system
[27,47-49]. In the present study, we found a strong up-
regulation of membrane-bound HSP70 by As2O3 treat-
ment, but not by the calcium ionophore A23187. This
upregulation of HSP70 by As2O3 strictly paralleled
the induction of B220 on EL-4, BW5147, Jurkat and
HPB-ALL T-cell lines (Table 1). Consequently, As2O3-
sensitive EL-4 cells expressed both high levels of
HSP70 and B220, whereas low expression levels of HSP70
and B220 were found on As2O3-resistant HPB-ALL
cells. Likewise, constitutive expression of B220 on As2O3-
resistant L1210 cells was associated with low expression
levels of membrane-bound HSP70. In vivo, the direct
cytotoxic effects of As2O3 could be amplified by the
upregulation of membrane-bound HSP70 on tumor
cells, which might facilitate tumor immune rejection.
CD45 is known to positively regulate antigen-receptor
signaling during activation of normal T and B cells via
dephosphorylation of src kinases, and to negatively regu-
late cytokine receptor signaling via dephosphorylation of
JAK kinases [17,18]. In this study, we show that the
modulation of B220 cell surface expression plays an im-
portant role in determining the sensitivity of leukemic T
cells to As2O3 and calcium ionophore A23187 cytotox-
icity. In addition, we found that As2O3 treatment re-
presses nuclear translocation of NF-κB p50 in a dose
dependent manner. Moreover nuclear translocation of
NF-κB p50 was increased in CD45-deficient Jurkat T cell
line (clone J45.01) after treatment with As2O3, suggest-
ing a link between B220 and NF-κB signaling pathways.
In conclusion, on a panel of mouse and human
leukemic T-cell lines, we have presented evidence for a
tight correlation between the induction of B220 mem-
brane expression and their sensitivity to cell death in-
duced by As2O3 or A23187. Our data strongly support
the hypothesis that B220 plays a checkpoint role in
death pathways. This could provide additional tools to
potentiate As2O3 therapy against leukemic T cells.Conclusions
In contrast to As2O3-treated APL cells, GSH content
and O2
− production do not play a significant role in
As2O3 sensitivity of leukemic T cells, suggesting the ex-
istence of additional factors determining the sensitivity
of T cells to As2O3 cytotoxicity. The B220 isoform of
transmembrane tyrosine phosphatase CD45 may be one
such factor. Indeed, we show that As2O3 treatment in-
duces B220 plasma membrane expression and cell death
in leukemic T-cell lines in a dose and time dependent
manner. The levels of B220 induction on the T-cell lines
strictly correlate with both the extent and form of cell
death. Leukemic T cells died by an apoptotic form of cell
death when high levels of B220 membrane expression
were achieved with low doses of As2O3. Taken together,
our data suggest that transmembrane tyrosine phosphat-
ase B220 plays a checkpoint role in apoptotic pathways
since its expression is markedly and rapidly induced on
the surface of T cells undergoing apoptosis.Materials and methods
Reagents
Arsenic trioxide (As2O3), phorbol 12-myristate 13-acetate
(PMA) and 4′,6-diamidino-2-phenylindole (DAPI) were
purchased from Sigma-Aldrich (St. Louis, MO), and
Calcium ionophore A23187 was from Calbiochem (EMD
Biosciences Inc, San Diego, CA). As2O3 was dissolved in
1 M NaOH, and stored as a 330 mM stock solution, which
was further diluted to 5 mM with phosphate-buffered
saline (PBS).Cell culture and cell treatment
Leukemic cell lines used in this study included mouse
T-cell lines EL-4, BW5147 and L1210, human T-cell
lines HPB-ALL, Jurkat (clone E6-1) and CD45 deficient
variant of the E6-1 clone of Jurkat (clone J45.01) (European
Collection of Cell Cultures), and human acute promyelocy-
tic leukemia cell line NB4. Leukemic T cell lines (EL-4,
BW5147, L1210, Jurkat (clone E6-1), HPB-ALL), and APL
derived cell line NB4 were kindly provided by Dr Colette
Kanellopoulos-Langevin (Centre for Inflammation
Research, INSERM, Hôpital Bichat, Paris, France) and
Dr Jacqueline Robert-Lézénès (Inserm U940, Hôpital
Saint-Louis, Paris, France), respectively. All cells were
grown in RPMI 1640 containing Glutamax (Invitrogen,
Cergy Pontoise, France) and supplemented with 10%
heat-inactivated fetal calf serum, 50 U/ml penicillin
and 50 μg/ml streptomycin at 37°C in a humidified 5%
CO2 atmosphere. This culture medium will be referred
to as complete medium. To avoid possible effects of
cell density on cell growth and survival, cells were
maintained at less than 5 × 105 cells/ml with daily
adjusting cell density through the addition of fresh
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blue dye exclusion assay.
Leukemic T cells were seeded in 12-well plates at a
density of 1 × 105 cells /ml and incubated in complete
medium alone or in the presence of different concentra-
tions of As2O3 or calcium ionophore A23187 at 37°C for
12, 24 and 48 h depending on the experiment.
Flow cytometry and imaging flow cytometry
The expression levels of cell surface markers on un-
treated and As2O3- or A23187-treated leukemic T-cell
lines was analyzed by flow cytometry using either fluor-
escein isothiocyanate (FITC)-, phycoerythrin (PE)-, allo-
phycocyanin (APC)- or biotin-conjugated monoclonal
antibodies (mAb): rat anti-mouse Thy-1.2/CD90.2 (clone
53–2.1), anti-CD45 (clone 2D1), anti-B220/CD45R (clone
RA3-6B2), anti-mouse and human CD69 (clone H1.2 F3
and FN50), anti-mouse and human Fas (clone Jo2 and
DX2), anti-mouse and human FasL (clone MFL3 and
NOK-1) and anti-HSP70 (clone SMC-103A) (all from
eBioscience, CliniSciences, Montrouge, France), and rat
IgG2a, mouse IgG, mouse IgG1, and Armenian hamster
IgG1 as the isotype control (eBiosciences). Use of mAb
to mouse and human Fcγ receptor (PharMingen, BD
Bioscience, San Jose, CA) avoided non-specific anti-
body binding.
The subcellular localization of B220/CD45R molecules
was determined by imaging flow cytometry, following the
protocol supplied by the manufacturer (Amnis Corp., Seattle,
WA). Briefly, cells (1 × 106) stained with PE-conjugated anti-
B220/CD45R mAbs and DAPI were run on an ImageStream
apparatus (ImagoSeine, Institut Jacques Monod, CNRS-
Université Paris Diderot, France). At least 10,000 images
were collected per sample at 40× or 60× magnification,
and analyzed using IDEAS image-analysis software
(Amnis Corp.).
Cell proliferation, cell death and caspase activation assay
Total cell numbers in untreated and As2O3-treated
groups were determined by flow cytometry by acquiring
events for a fixed time period of 1 min. As2O3- and Cal-
cium ionophore-induced cell death was analyzed by propi-
dium iodide (PI) (Invitrogen) staining, and flow cytometry.
Among PI+ cells, to discriminate between apoptotic and
necrotic cells, the cells were stained using either FITC-
conjugated Annexin V (PharMingen) or CaspaTag Caspase
8 or Caspase 9 In situ Assay Kit, Fluorescein according to
the manufacturer's instructions (Chemicon, Temecula,
CA). Annexin V staining and the levels of active caspase-8
and caspase-9 were measured by flow cytometry.
Analysis of reduced glutathione content and O2
− production
GSH content and O2
− production in T-cell lines treated
or not with As2O3 were measured by flow cytometryusing 100 nM CellTracker probe CMFDA and 5 μM
DHE probes, respectively, following the manufacturer’s
instructions (Molecular Probes, Eugene, OR).
B220/CD45R mRNA quantification by RT-PCR
Total RNA was extracted from 5 × 106 leukemic T cells
treated or not with As2O3 using the RNeasy Plus Mini
kit (Qiagen, Courtaboeuf, France) following the manu-
facturer’s instructions and was used to generate cDNA
utilizing oligo(dT) primer and SuperScript II Reverse
Transcriptase (Invitrogen). PCR were conducted for
25 cycles with the following primer pairs: B220/CD45R
forward primer (5'-CAC ATA TCA TCC AGG TGT
GTT ATC C-3') and reverse primer (5'-GTC CTC TCC
CCT GGC ACA CCT G-3'); β-actin forward primer
(5'-ATC GTG GGC CGC CCT AGG CAC-3') and reverse
primer (5'-TGG CCT TAG GGT TCA GAG GGG C-3').
Semi-quantitative determination (ImageJ densitometric
analysis software program) of B220 cDNA, present in each
of the various samples, was normalized with respect to the
concentration of internal control cDNA (β-actin) detected
in the same sample, and B220/ β-actin cDNA ratios were
calculated.
Quantitative measurement of NF-κB activation
Nuclear extracts were prepared from 8 × 106 leukemic
T cells treated or not with As2O3. The protein from
nuclear extracts was quantified by the Bradford method
(Bio-Rad, France). An equal amount of nuclear extract
(5 μg) was assayed for NF-κB p50 activity using a TransAm
NFκB p50 Transcription Factor Assay Kit according to the
manufacturer’s recommendations (ActiveMotif, Rixensart,
Belgium).
Statistical analyses
Data are reported as fluorescence means ± SE. Signifi-
cant differences between sample means were determined
using the Student t test. Statistical significance was ac-
cepted at P ≤0.05.
Additional files
Additional file 1: Figure S1. (A) Cell morphology of As2O3-treated T-cell
lines. APL-derived NB4 cells as well as EL-4, BW5147, L1210, Jurkat,
CD45-deficient Jurkat variant (J45.01) and HPB-ALL T-cell lines were
treated for 24 h with As2O3 in doses ranging from 1 to 20 μM. Cells
were then analyzed by flow cytometry with respect to size (FSC) and
granulosity (SSC). Regions R1 and R2 identified on a FSC vs. SSC dot plot
encompassed cells with FSCint/lowSSChigh and FSChighSSClow, respectively. At
least 20,000 events were analyzed for each sample. FSC vs. SSC dot plots on
murine EL-4 cells and human Jurkat cells are representative of more than 10
independent experiments. (B) Basal level of CD45 plasma membrane
expression. Jurkat (■) and CD45-deficient Jurkat variant (J45.01) (□) cells were
stained with PE-conjugated anti-CD45 mAb (clone 2D1) or PE-conjugated
rat IgG2a isotype control, and then analyzed by flow cytometry. (C)
B220 mRNA expression in As2O3-treated T-cell lines. RT-PCR analysis
were performed to assess the levels of B220 mRNA in EL-4 and
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As2O3 for 3, 6 and 9 h. Results are representative of two other experiments.
Additional file 2: Figure S2. (A) Constitutive B220/CD45R cell surface
expression on CD90+ L1210 T cells. Cells were labeled with APC-conjugated
anti-CD90 and PE-conjugated anti-B220/CD45R mAbs, or fluorescent isotype
control, and then analyzed by flow cytometry. (B) B220 expression on
As2O3-treated cells. L1210 T cells were treated without or with As2O3 for
24 h in doses ranging from 1 to 20 μM. L1210 cells were then stained with
PE-conjugated anti-B220/CD45R mAb or PE-conjugated rat IgG2a isotype
control, and further analyzed by flow cytometry with respect to size (FSC)
versus granulosity (SSC) and B220 expression. FSC vs. SSC dot plots were
used to define gates R1 and R2 with FSCint/lowSSChigh and FSChighSSClow,
respectively. B220 histograms were then gated in R1 and R2 to determine
the percentages of cells expressing B220 (n =10 independent experi-
ments). At least 20,000 events were analyzed for each sample. (C) HSP70
induction on As2O3-treated cells. L1210 T cells stained with anti-B220 and
anti-HSP70 antibodies were analyzed by flow cytometry as described in
Figure 3B. (D) FasL induction on Ca2+ ionophore treated cells. Histograms
obtained with PE-conjugated Armenian hamster (clone MFL3) anti-FasL
mAb (open histogram) are overlaid on histograms obtained with PE-
conjugated Armenian hamster isotype control (shaded histogram) (n = 3
independent experiments). At least 20,000 events were analyzed for
each sample.
Additional file 3: Figure S3. Duration of B220/CD45R membrane
expression upon As2O3 treatment. EL-4 and Jurkat T cells were cultured
in the absence or in the presence of 1, 2, 4 or 8 μM As2O3 for 24 h. Then,
cells were extensively washed with PBS to eliminate all traces of As2O3,
and cultured for 9 additional days. Expression of B220 was measured by
flow cytometry at the time of As2O3 removal (referred to as day 0) and 1
to 9 days after As2O3 was removed. At least 20,000 events were analyzed
for each sample. Dot plots of FSC vs. SSC on 8 μM As2O3-treated EL-4
and Jurkat cells are representative of more than 3 independent experiments.
Graphs report the percentages of B220+ EL-4 or B220+ Jurkat cells at the
indicated time-points and concentrations of As2O3, with the same isotype
control labelling as in Figure 3.Abbreviations
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